SEC 13F Intelligence

Managers / Q1 2026

Commodore Capital LP

CIK 0001831942 · 444 MADISON AVENUE, 35TH FLOOR, NEW YORK, NY, 10022 · 212-256-8600

Reported Value
$1.7B
Q1 2026
Positions
36
Filings on Record
25
2019–present window
Filed
May 15, 2026
original filing

Summary

Commodore Capital LP reported $1.7B in U.S.-listed holdings across 36 positions for Q1 2026.

Its largest position, RLAY, represents 9.8% of the portfolio.

Compared with Q4 2025, the fund opened 13 new positions and exited 10.

Portfolio Metrics

Turnover
+23.7%
vs prior filed quarter
Top-10 Concentration
+61.3%
share of reported value
Largest Position
+9.8%
Relay Therapeutics
New / Exited
13 / 10
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $184MQ4 ’20Q1 ’21: $254MQ2 ’21: $290MQ3 ’21: $379MQ3 ’21Q4 ’21: $432MQ1 ’22: $448MQ2 ’22: $473MQ2 ’22Q3 ’22: $622MQ2 ’23: $890MQ3 ’23: $856MQ3 ’23Q4 ’23: $1.1BQ1 ’24: $1.5BQ2 ’24: $1.5BQ2 ’24Q3 ’24: $1.6BQ4 ’24: $1.4BQ1 ’25: $1.4BQ1 ’25Q2 ’25: $1.4BQ3 ’25: $2.0BQ4 ’25: $1.5BQ4 ’25Q1 ’26: $1.7Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 86.9%Other: 13.1%
  • Common Stock · 86.9% · $1.5B
  • Other · 13.1% · $227M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ERASERASCA INCNEW+3.17M3.17M+$51M$51M
DMRADAMORA THERAPEUTICS INCNEW+1.94M1.94M+$50M$50M
DFTXDEFINIUM THERAPEUTICS INCNEW+2.00M2.00M+$38M$38M
EYPTEYEPOINT INCNEW+2.83M2.83M+$36M$36M
CRVSCORVUS PHARMACEUTICALS INCNEW+2.26M2.26M+$33M$33M
CATXPERSPECTIVE THERAPEUTICS INCNEW+6.34M6.34M+$26M$26M
OCULOCULAR THERAPEUTIX INCNEW+2.58M2.58M+$22M$22M
IPSCCENTURY THERAPEUTICS INCNEW+8.70M8.70M+$20M$20M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

36 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RLAYRELAY THERAPEUTICS INChistory →COM9.79%$169M17.00M
2ALKERMES PLCSHS8.59%$149M4.20M
3ELVNENLIVEN THERAPEUTICS INChistory →COM7.43%$128M3.27M
4COGTCOGENT BIOSCIENCES INChistory →COM6.43%$111M2.89M
5SYRESPYRE THERAPEUTICS INChistory →COM NEW5.58%$96M1.91M
6TYRATYRA BIOSCIENCES INChistory →COM5.48%$95M2.48M
7TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW4.95%$86M2.70M
8NUVLNUVALENT INChistory →COM4.94%$85M833.6K
9AMLXAMYLYX PHARMACEUTICALS INChistory →COM4.54%$79M5.65M
10KYMRKYMERA THERAPEUTICS INChistory →COM3.61%$62M750.0K
11ANROALTO NEUROSCIENCE INChistory →COM SHS3.54%$61M2.72M
12PHARVARIS N VCOM3.14%$54M1.92M
13ERASERASCA INChistory →COM2.97%$51M3.17M
14DMRADAMORA THERAPEUTICS INChistory →COM NEW2.91%$50M1.94M
15XENEXENON PHARMACEUTICALS INChistory →COM2.78%$48M825.0K
16DFTXDEFINIUM THERAPEUTICS INChistory →COM SHS2.19%$38M2.00M
17LBRXLB PHARMACEUTICALS INChistory →COM SHS2.14%$37M1.50M
18EYPTEYEPOINT INChistory →COM NEW2.11%$36M2.83M
19NRIXNURIX THERAPEUTICS INChistory →COM2.04%$35M2.27M
20CRVSCORVUS PHARMACEUTICALS INChistory →COM1.91%$33M2.26M
21ASMBASSEMBLY BIOSCIENCES INChistory →COM NEW1.61%$28M1.00M
22CATXPERSPECTIVE THERAPEUTICS INChistory →COM NEW1.53%$26M6.34M
23SLNOEURSOLENO THERAPEUTICS INChistory →COM1.26%$22M652.4K
24OCULOCULAR THERAPEUTIX INChistory →COM1.26%$22M2.58M
25IPSCCENTURY THERAPEUTICS INChistory →COM1.14%$20M8.70M
26ZURA BIO LTDCLASS A ORD SHS1.12%$19M3.25M
27SABSSAB BIOTHERAPEUTICS INChistory →COM NEW0.98%$17M4.40M
28PALIPALISADE BIO INChistory →COM0.73%$13M7.18M
29KPTIKARYOPHARM THERAPEUTICS INChistory →COM NEW0.63%$11M1.95M
30IKTINHIBIKASE THERAPEUTICS INCCOM NEW0.52%$9M5.40M
31ANTXAN2 THERAPEUTICS INCCOM0.46%$8M2.33M
32PEPGPEPGEN INCCOM0.46%$8M4.47M
33AVTXAVALO THERAPEUTICS INCCOM NEW0.42%$7M483.0K
34HELIX ACQUISITION CORP IIIUSD CL A ORD SHS0.29%$5M500.0K
35LONALEONABIO INCCOM0.28%$5M464.4K
36RLMDRELMADA THERAPEUTICS INCCOM0.26%$4M633.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.7B36May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.5B33Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$2.0B37Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.4B33Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.4B31May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.4B31Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.6B36Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.5B35Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.5B39May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.1B32Feb 14, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$856M30Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$890M26Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review32May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review35Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$622M30Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$473M24Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$448M27May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$432M25Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$379M29Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$290M29Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$254M31May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$184M28Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.